Heart Disease Less Likely in Lupus Patients in Remission for 5 or More Years

Heart Disease Less Likely in Lupus Patients in Remission for 5 or More Years

Patients with systemic lupus erythematosus in remission for five or more years are at a lower risk of cardiovascular disease than those with shorter remission times or who fail to enter remission, a retrospective study reports.

The study, “Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study,” was published in Clinical Rheumatology.

Transplantation of Placenta Cells May Halt Inflammation in Lupus Patients

Transplantation of Placenta Cells May Halt Inflammation in Lupus Patients

The transplantation of human placental cells was found to suppress immune and inflammatory responses in a mouse model of systemic lupus erythematosus (SLE), suggesting a potential new therapeutic strategy for lupus, a study shows.

The study, “Therapeutic effect of human amniotic epithelial cells in murine models of Hashimoto’s thyroiditis and Systemic lupus erythematosus,” was published in the journal Cytotherapy.

Study suggests Virgin Olive Oil May Help Reduce SLE Activity

Study suggests Virgin Olive Oil May Help Reduce SLE Activity

Virgin olive oil, especially its phenol components, showed anti-inflammatory properties in mice with systemic lupus erythematosus (SLE) and in human immune cells, according to a new Spanish study. The findings suggest future use in SLE treatment.

The research, “Virgin olive oil and its phenol fraction modulate monocyte/macrophage functionality: a potential therapeutic strategy in the treatment of systemic lupus erythematosus,” was published in the British Journal of Nutrition.

Lupus Overlap in Scleroderma Patients Does Not Seem to Affect Survival

Lupus Overlap in Scleroderma Patients Does Not Seem to Affect Survival

Patients with both scleroderma and systemic lupus erythematosus (SLE) are younger at diagnosis, are more often women, and have less skin manifestations, but most importantly, show similar survival rates as those without lupus, according to a study.

The study, “Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome,” was published in The Journal of Rheumatology.

Infection Is Leading Cause of Death in Lupus Patients in China

Infection Is Leading Cause of Death in Lupus Patients in China

In China, mortality rates are higher among women with systemic lupus erythematosus(SLE) than men, with infection being the leading cause of death, a study reports.

According to the researchers, risk factors for poorer outcomes include older age at disease onset, infection, autoimmune anemia, low platelet levels, and pulmonary arterial hypertension.

Lupus affects more women than men. Why? New study explores

Lupus affects more women than men. Why? New study explores

Lupus affects nine times more women than men. Experts know that lupus erythematosus, SLE, or lupus affects many more women than men, but none of them can explain why. Now that University of Houston biomedical engineer Chandra Mohan has the funding, he has set out to determine why.

Prof. Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, has $2 million to solve the mystery.

Study reveals early signs of cardiac impairment in patients with newly diagnosed lupus

Study reveals early signs of cardiac impairment in patients with newly diagnosed lupus

Cardiovascular disease is a leading cause of death in patients with lupus, a systemic autoimmune disease. In a new study in Arthritis & Rheumatology—a journal published by Wiley on behalf of the American College of Rheumatology—imaging tests revealed signs of cardiac impairment in patients newly diagnosed with lupus, even before any symptoms of chest discomfort.

Lilly to progress Olumiant into Phase 3 for lupus

Lilly to progress Olumiant into Phase 3 for lupus

The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).

According to the data, a statistically significant proportion of patients treated with 4mg of Olumiant (baricitinib) achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, thus meeting the primary endpoint of the trial.